AnaptysBio, Celgene sign strategic antibody discovery partnership
AnaptysBio has entered into a strategic partnership with Celgene to develop antibodies against multiple therapeutic targets.
As per the agreement, AnaptysBio will use its SHM-XEL platform to produce therapeutic antibodies to oncology and inflammation-related targets.
Celgene will gain worldwide rights to develop and commercialize antibodies discovered by AnaptysBio.
AnaptysBio is eligible to receive an upfront payment, preclinical and clinical milestone payments from Celgene, as well as royalties upon sales of each product resulting from the partnership.
AnaptysBio president and chief executive officer Hamza Suria said: "We look forward to advancing novel antibody therapeutics with Celgene, in parallel with our internal pipeline programs."
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $250